Published mark
Sanofi
NASDAQ: SNY. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:6f05ca0c-a52c-469e-bd04-7efad28236e7
- SEC CIK
- 0001121404
- Website
- www.sanofi.com Open
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 23, 2026
- Newest evidence
- Sep 1, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Belén GarijoChief Executive Officer
- Chair
- Frédéric Oudéa
- Independent
- Not published
- Published claims
- 385 distinct sources
- Evidence records
- 90 pinned
- Source conflicts
- 0None open
Built from 5 distinct sources and 9 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Chief Executive Officer | Belén Garijo | Not captured | unknown | Source reportedE3 |
| Executive Vice President, Manufacturing & Supply | Brendan O'Callaghan | Not captured | unknown | Source reportedE3 |
| Executive Vice President, Finance | François Roger | Not captured | unknown | Source reportedE3 |
| Executive Vice President, General Counsel | Jamie Haney | Not captured | unknown | Source reportedE3 |
| Executive Vice President, Specialty Care | Manuela Buxo | Not captured | unknown | Source reportedE3 |
| Executive VP & Chief People Officer | Natalie Bickford | Not captured | unknown | Source reportedE4 |
| Executive Vice President of General Medicines | Olivier Charmeil | Not captured | unknown | Source reportedE5 |
| CEO & Director | Paul Hudson | Not captured | unknown | Source reportedE6 |
| Executive Vice President, Head of Research & Development | Paulo Fontoura | Not captured | unknown | Source reportedE3 |
| Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing | Pierre Chancel | Not captured | unknown | Source reportedE7 |
| Executive VP & General Counsel | Roy Papatheodorou | Not captured | unknown | Source reportedE8 |
| Executive Vice President, General Medicines | Thomas Grenier | Not captured | unknown | Source reportedE3 |
| Executive Vice President, Vaccines | Thomas Triomphe | Not captured | unknown | Source reportedE3 |
| Executive Vice President, Chief People Officer, ad interim | Véronique Jaillet | Not captured | unknown | Source reportedE3 |
Board of directors
Evidence| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Anne-Françoise Nesmes | Independent | Not published | None published | Source reportedE2 |
| Antoine Yver | Independent | Not published | None published | Source reportedE2 |
| Barbara Lavernos | Independence not published | Not published | None published | Source reportedE2 |
| Belén Garijo | Independence not published | Not published | None published | Source reportedE2 |
| Carole Ferrand | Independent | Not published | None published | Source reportedE2 |
| Christel Heydemann | Independent | Not published | None published | Source reportedE2 |
| Christophe Babule | Independence not published | Not published | None published | Source reportedE2 |
| Clotilde Delbos | Independent | Not published | None published | Source reportedE2 |
| Emile Voest | Independent | Not published | None published | Source reportedE2 |
| Frédéric Oudéa | Not independentChair | Not published | None published | Source reportedE2 |
| Humberto De Sousa | Not independent | Not published | None published | Source reportedE2 |
| Jean-Paul Kress | Independent | Not published | None published | Source reportedE2 |
| John Sundy | Independent | Not published | None published | Source reportedE2 |
| Lise Kingo | Independent | Not published | None published | Source reportedE2 |
| Rachel Duan | Independent | Not published | None published | Source reportedE2 |
| Wolfgang Laux | Not independent | Not published | None published | Source reportedE2 |
Committees and risk ownership
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerBelén Garijo, Chief Executive Officer
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceIndex MembershipCAC 40 (PX1)
Security ListingSNY (NASDAQ)
Security ListingSNYNF (OTC)
Security ListingSAN (EURONEXT PARIS)
Index memberships1 membership attached to a specific security and listing.Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.
PX1
Source reportedAs of Oct 23, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
| Index | Security | Status | Effective | Verification | Source |
|---|---|---|---|---|---|
| CAC 40 (Euronext) | EURONEXT PARIS: SAN | current | Jun 30, 2026 | provider verified | Euronext CAC 40 free composition PDF (partial) |
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameSanofi
Entity StatusPublic listing published
Published FactUS
Published FactHealthcare
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- CommitteesNot reviewed. Committee mandates show where oversight is delegated.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- EventsInsufficient evidence. Governance events are derived from temporal changes in governed records.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Belén GarijoChief Executive Officer; Directorcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:23, company:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:11
- Brendan O'CallaghanExecutive Vice President, Manufacturing & Supplycompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:24
- François RogerExecutive Vice President, Financecompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:25
- Jamie HaneyExecutive Vice President, General Counselcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:26
- Manuela BuxoExecutive Vice President, Specialty Carecompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:27
- Natalie BickfordExecutive VP & Chief People Officercompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:28
- Olivier CharmeilExecutive Vice President of General Medicinescompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:29
- Paul HudsonCEO & Directorcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:30
- Paulo FontouraExecutive Vice President, Head of Research & Developmentcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:31
- Pierre ChancelSenior Vice President of Global Diabetes and Senior Vice President of Global Marketingcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:32
- Roy PapatheodorouExecutive VP & General Counselcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:33
- Thomas GrenierExecutive Vice President, General Medicinescompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:34
- Thomas TriompheExecutive Vice President, Vaccinescompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:35
- Véronique JailletExecutive Vice President, Chief People Officer, ad interimcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:36
- Anne-Françoise NesmesIndependent directorcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:8
- Antoine YverIndependent directorcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:9
- Barbara LavernosDirectorcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:10
- Carole FerrandIndependent directorcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:12
- Christel HeydemannIndependent directorcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:13
- Christophe BabuleDirectorcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:14
- Clotilde DelbosIndependent directorcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:15
- Emile VoestIndependent directorcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:16
- Frédéric OudéaChairman of the Board of Directorscompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:7
- Humberto De SousaDirector representing employeescompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:17
- Jean-Paul KressIndependent directorcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:18
- John SundyIndependent directorcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:19
- Lise KingoIndependent directorcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:20
- Rachel DuanIndependent directorcompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:21
- Wolfgang LauxDirector representing employeescompany:6f05ca0c-a52c-469e-bd04-7efad28236e7:leadership_role:22
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 9 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 23, 2026. Cited by 7 Claims.
- E2official company source. Published Sep 1, 2026. Retrieved Sep 2, 2026. Cited by 16 Claims.
- E3official company source. Published Sep 1, 2026. Retrieved Sep 2, 2026. Cited by 9 Claims.
- E4other. Published Apr 24, 2026. Retrieved Apr 24, 2026. Cited by 1 Claim.
- E5other. Published Apr 24, 2026. Retrieved Apr 24, 2026. Cited by 1 Claim.
- E6other. Published Apr 24, 2026. Retrieved Apr 24, 2026. Cited by 1 Claim.
- E7other. Published Apr 24, 2026. Retrieved Apr 24, 2026. Cited by 1 Claim.
- E8other. Published Apr 24, 2026. Retrieved Apr 24, 2026. Cited by 1 Claim.
- E9Euronext CAC 40 free composition PDF (partial). index provider. Retrieved Sep 2, 2026. Cited by 1 Claim.
Version history
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 23, 2026No published record changes are available in this projection.